Business combination, contingent value right received for each share.

No definition available.

Name:	ikna_BusinessCombinationContingentValueRightReceivedForEachShare
Namespace Prefix:	ikna_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of net proceeds from potential monetization of legacy programs receivable.

+ References

No definition available.

+ Details

Name:	ikna_PercentageOfNetProceedsFromPotentialMonetizationOfLegacyProgramsReceivable
Namespace Prefix:	ikna_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479907/805-20-50-5

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=ikna_PionyrImmunotherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_NonvotingCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Acquisition of Pionyr Therapeutics - Additional Information (Details) - Pionyr Immunotherapeutics, Inc - USD ($) $ in Millions	Oct. 11, 2023	Aug. 04, 2023
Business Acquisition [Line Items]
Business acquisition, transaction cost		$ 1.4
Common Stock
Business Acquisition [Line Items]
Business acquisition, shares issued		1,800,652
Non-voting Common Stock
Business Acquisition [Line Items]
Business acquisition, shares issued		153,121
Series A Preferred Stock
Business Acquisition [Line Items]
Business acquisition, shares issued		4,153,439
Subsequent Event
Business Acquisition [Line Items]
Business acquisition, contingent value right received for each share	1
Percentage of net proceeds from potential monetization of legacy programs receivable	50.00%